The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission followin...
The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma
About this item
Full title
Author / Creator
Jaglowski, S M , Ruppert, A S , Hofmeister, C C , Elder, P , Blum, W , Klisovic, R , Vasu, S , Penza, S , Efebera, Y A , Benson, D M , Devine, S M and Andritsos, L A
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Patients who undergo autologous stem cell transplant (ASCT) for hematologic malignancies frequently have multiple comorbidities. The hematopoietic cell transplantation comorbidity index (HCT-CI), a transplant-specific modification of the Charlson comorbidity index, can predict risk of readmission following allogeneic stem cell transplant. Its utili...
Alternative Titles
Full title
The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4192086
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4192086
Other Identifiers
ISSN
0268-3369
E-ISSN
1476-5365
DOI
10.1038/bmt.2014.155
